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Objective: This work was aimed to prove that release/formation of endogenous endothelin acting in an autocrine/paracrine fashion
contributes to the increase in contractility promoted by a low dose of angiotensin II. Methods: Isolated cat papillary muscles were used for
force, pHi, [Na
+]i and [Ca
2 +]i measurements and isolated cat myocytes for patch-clamp experiments. Results: In papillary muscles, 1.0 nmol/
l angiotensin II increased force by 23F 2% (n = 4, P< 0.05), [Na+]i by 2.2F 0.2 mmol/l (n = 4, P < 0.05), and peak (but not diastolic) Ca
2 +
from 0.674F 0.11 to 0.768F 0.13 Amol/l (n = 4, P < 0.05), without affecting pHi. Force and [Na+]i increase were abolished by inhibition of
the Na+/H+ exchanger (NHE) with the inhibitor HOE642, blockade of endothelin receptors with the nonselective antagonist TAK044 and by
inhibition of the endothelin-converting enzyme with phosphoramidon. Force but not [Na+]i increase was abolished by inhibition of reverse
Na+/Ca2 + exchange (NCX) with the inhibitor KB-R7943. Similar increase in force (21F 2%, n = 4, P < 0.05) and in [Na+]i (2.4F 0.4 mmol/
l, n = 4, P< 0.05) that were also suppressed by TAK044 and HOE642 were induced by exogenous 5.0 nmol/l endothelin-1. KB-R7943
reverted the endothelin-1 effect on force but not on [Na+]i. In isolated myocytes, exogenous endothelin-1 dose-dependently increased the
NCX current and shifted the NCX reversal potential (ENCX) to a more negative value (DENCX:  10F 3 and  17F 5 mV, with 1 and 10
nmol/l endothelin-1, respectively, n = 12). The latter effect was prevented by HOE642. Conclusion: Taken together, the results indicate that a
low dose of angiotensin II induces release of endothelin, which, in autocrine/paracrine fashion activates the Na+/H+ exchanger, increases
[Na+]i and changes ENCX, promoting the influx of Ca
2 + that leads to a positive inotropic effect (PIE).
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1. Introduction and fibrosis [5]. However, whether or not the release/ 3 August 2019Many of the effects previously attributed to angiotensin
II (Ang II) have been shown to be mediated by autocrine/
paracrine release/formation of endothelin (ET) [1–12]. Ang
II releases/forms ET from many different types of tissue
[1–12] including the heart [3–5]. In the heart, the mech-
anism has been associated with cardiac hypertrophy [3,4]0008-6363/$ - see front matter D 2003 European Society of Cardiology. Publishe
doi:10.1016/j.cardiores.2003.09.004
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Provincia de Buenos Aires, Argentina.formation of ET is also involved in the positive inotropic
effect (PIE) of Ang II has not been explored. In previous
studies, and based on pharmacological interventions, we
suggested the existence of an autocrine/paracrine mecha-
nism by which myocardial stretch induces the release of
preformed Ang II, which will increase the release/formation
of ET [13–15]. Then ET, by activating the Na+/H+ ex-
changer (NHE), will increase [Na+]i and promote Ca
2 +
influx through the Na+/Ca2 + exchanger (NCX). Although
each step of this chain of events was pharmacologically
confirmed [13–15], evidence that exogenously applied Ang
II releases ET and increases myocardial contractility is still
lacking.
The aim of this study was to prove that a low dose of
Ang II promotes a PIE by increasing the release/formationd by Elsevier B.V. All rights reserved.
N.G. Pe´rez et al. / Cardiovascular Research 60 (2003) 589–597590of ET by myocardial cells and to identify the subsequent
underlying mechanism.D
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The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996).
2.1. Multicellular preparations
As previously described [15], cat papillary muscles from
the right ventricle were mounted in a perfusion chamber
placed on the stage of an inverted microscope for force and
epifluorescence measurements and superfused at constant
rate (5 ml/min) with a CO2/HCO3
-buffered solution con-
taining (mmol/l) 128.3 NaCl, 4.5 KCl, 1.35 CaCl2, 20.23
NaHCO3, 1.05 MgSO4, 11.0 glucose, equilibrated with 5%
CO2/95% O2 at 30 jC (solution pHf 7.39). To avoid theFig. 1. Inotropic effect of 1 nmol/l Ang II on contractility of isolated cat papillary m
by Ang II (A). Blocking the AT1 receptors with losartan (B), nonspecific blockade
with phosphoramidon (D) or NHE-1 blockade with HOE642 (E) abolished the inc
30 min of incubation with the peptide, expressed as percent of baseline (pre-Ang II
its AT1 receptors, promotes release/formation of ET that activates the NHE-1 andcontribution of catecholamine released by nerve endings in
the PIE of Ang II [16], prazosin plus atenolol (1.0 Amol/
l each) were used. The muscles were paced at 0.2 Hz at a
voltage 10% over threshold, and isometric contractions were
recorded. Cross-sectional area (0.75 of the product of
thickness by width) was used to normalise the force records
obtained with a silicon strain gauge (model AEM 801,
SensoNor). After determining slack length, each muscle
was progressively stretched to the length at which twitch-
developed force was maximal (Lmax). Then, they were
shortened to obtain the 95% of the maximal twitch force
(length that approximated 98% of Lmax) and maintained at
this length throughout the rest of the experiment. Changes in
[Na+]i and pHi were performed by epifluorescence with
sodium-binding benzofuran isophthalate (SBFI, AM form)
or 2V,7V-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein
(BCECF, AM form), respectively, as previously described
[15]. Briefly, the esters were prepared as 1 mmol/l solution
in dimethylsulfoxide (DMSO); this solution was mixed with
Pluronic F-127 (20% wt./wt. in DMSO) at a ratio 4:1 to help
disperse the indicators in the loading medium. Loading timeuscles. Typical force record showing the positive inotropic effect promoted
of ET receptors with TAK044 (C), endothelin-converting enzyme inhibition
rease in contractility. Overall changes in developed force (DF) at the end of
) value (F, n = 4 each). These results suggest that exogenous Ang II, through
induces the increase in force. *indicates P< 0.05 vs. pre-Ang II value.
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/clasted 30 min with BCECF (final concentration 5 Amol/l)
and 2 h with SBFI (final concentration 10 Amol/l) at room
temperature (22–24 jC), followed in both cases by a 30–
60-min washout to allow the cleavage of the AM part of the
dyes by intracellular esterase. At the end of each experi-
ment, BCECF emitted fluorescence was calibrated in vivo
by the high K+-nigericin method [13–15]. Calibration of
SBFI fluorescence was made according to Harootunian et al.
[17] with 2.0 Amol/l gramicidin, 5.0 Amol/l monensin and
0.05 mmol/l ouabaine. Calibration media containing various
Na+ concentrations were made from appropriate mixtures of
high Na+ and high K+ solutions. In the case of Fura-2 AM,
the muscles were incubated with the dye for 1.5 h (final
concentration 5 Amol/l) followed, by a 30–60-min washout.
Contribution of fluorescence arising from dye in endothelial
cells was disregarded since no significant changes in the
absolute level of fluorescence was detected during pro-
longed (f 1.5 h) monitoring after inducing the selective
endothelial loss of the indicator by adding 100 nmol/
l ionomycin at the end of each experiment [18]. [Ca2 +]i
was calculated by the standard equation [Ca2 +]i =KdV
(RRmin)/(RmaxR). In vivo calibration of Fura-2 signals
gave values of 2.63, 2.11 and 0.511 for KdV, Rmax and Rmin,Fig. 2. Inotropic effect of 5 nmol/l ET-1. As in Fig. 1, typical force records of the e
D) are shown. Overall values of DF, expressed as percent of baseline (pre-ET-1) v
NHE-1 activity is mediated by its own receptors, since it was abolished by TAK04
(Fig. 1) indicates that Ang II acts through ET but not ET through Ang II. * Indirespectively. For all indicators, corresponding background
fluorescence levels at each wavelength was subtracted from
the respective signal before rationing.
2.2. Cell isolation
Cat cardiac myocytes were isolated as previously de-
scribed [19] and were placed in a perfusion chamber super-
fused at a constant rate of 1.5 ml/min at 30 jC. The patch-
clamp whole-cell configuration technique was used for
voltage-clamp recordings. According to the voltage protocol
described by Zhang et al. [20], whole-cell currents were
evoked by descending ramps from + 80 to  120 mV (dV/
dt = 0.4 mV/ms), applied from a holding potential of  80
mV. Prior to the descending ramp, the membrane potential
was held at + 80 mV for 30 ms in order to avoid current
contamination during the ramp with any residual uncom-
pensated capacitative current. Interpulse interval was 10 s.
2.3. Isolation NCX current (INCX)
The INCX was isolated as previously described [21]. The
NCX blocker NiCl2 (Ni
2 +, 10 mmol/l) was added to theffect of ET-1 alone (A) or after different pharmacological interventions (B–
alue, after 30 min (E, n = 4 each). The results show that the ET-1 effect on
4 but not by losartan. The fact that TAK044 abolished the effects of Ang II
cates P< 0.05 vs. pre-ET-1 value.
ardiovascres/article-abstract/60/3/589/335517 by guest on 23 August 2019
Fig. 3. Ang II and ET-1 induced NHE-1 activation. (A) Typical experiment and averaged results (n = 4) of the effect of 1.0 nmol/l Ang II on pHi. (B) Time
course of [Na+]i changes induced by Ang II and averaged values after 30 min, in control and after NHE-1 inhibition or ET receptors blockade. (C and D) Same
as (A) and (B), respectively, but after addition of a dose of exogenous ET-1 (5.0 nmol/l) equipotent to 1.0 nmol/l Ang II. These results show that despite the
lack of pHi change, there is an Ang II-induced NHE-1 stimulation detected by the increase in [Na
+]i that requires available ET receptors and that this effect can
be mimicked by an equipotent dose of exogenous ET-1. * Indicates P < 0.05 vs.
N.G. Pe´rez et al. / Cardiovascular Research 60 (2003) 589–597592
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/cardiovascres/aextracellular solution at the end of each experiment to obtain
the Ni2 +-sensitive currents, representing INCX. For each cell,
capacitative current was recorded to normalise the currents
for cell capacitance. Averaged cell capacitance was 131F 5
pF (n = 20).Fig. 4. Effects of ET-1 on INCX. Representative traces of whole-cell currents ev
(Control) and after successive additions of 1.0, 10.0 nmol/l ET-1 and 10.0 mmol/
obtained by subtracting the currents recorded in Ni2 + to those of control and ET
recorded in 12 myocytes are shown in (C). Bars compare the ratio between contro
Note that ET-1 dose-dependently increased both outward and inward INCX and s
§ Indicates P < 0.05 vs. 1.0 nmol/l ET-1.2.4. Pharmacological interventions
The effect of Ang II or ET-1 was assessed in the absence
and presence of 1.0 Amol/l HOE642 to inhibit the cardiac
Na+/H+ exchanger (NHE-1 isoform); 1.0 Amol/l losartan, to
pre-Ang II (B) or pre-ET-1 (D) value.oked by descending ramps recorded in a cat ventricular myocyte before
l Ni2 + to the bath solution (A). Ni2 +-sensitive currents, representing INCX,
-1 (B). Average values of ENCX obtained from the Ni
2 +-sensitive currents
l INCX and that in the presence of ET-1 at potentials of 0 and  80 mV (D).
hifted the ENCX to a more negative value. * Indicates P < 0.05 vs. control.
rticle-abstract/60/3/589/335517 by guest on 23 August 2019
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 httpblock the AT1 receptors; 1.0 Amol/l TAK044 for nonspecific
ET receptors blockade or 5.0 Amol/l KB-R7943, to inhibit
the reverse mode of the NCX. The effect of Ang II was also
assessed in the presence of 100 Amol/l phosphoramidon to
inhibit the endothelin-converting enzyme. In all cases, the
drugs were applied f 20 min before Ang II or ET-1, and
during this period, developed force (DF) did not change by
more than 3.0%. It was carefully checked that DF was at
steady state before adding any peptide.
2.5. Statistics
Data are expressed as meanF S.E.M. Paired or unpaired
Student’s t-test or one-way ANOVA followed by Student–
Newman–Keuls were used as appropriate. A P < 0.05 was
considered to indicate significant differences. s://academ
ic.oup.com
/cardiov3. Results
Fig. 1A shows the effect of 1.0 nmol/l Ang II on the
contractile behaviour of a cat isolated papillary muscle. The
concentration was selected to induce f 20% increase in
contractility. The averaged increase in force after 30 min of
Ang II was 23F 2% of control (n = 4, P < 0.05, Fig. 1F).Fig. 5. Effects of ET-1 on INCX in the presence of NHE-1 inhibition. Representativ
of 1.0, 10.0 nmol/l ET-1 and 10.0 mmol/l Ni2 + in the continuous presence of 1.0 A
panel (A). Average values of ENCX obtained from the Ni
2 +-sensitive currents recor
that in the presence of ET-1 at potentials of 0 and  80 mV (D). Note that NHE-1
no rise in [Na+]i was detected when NHE-1 activity was inhibited, as was shownThis effect was completely abolished by either AT1 receptor
blockade with losartan (Fig. 1B and F), nonspecific ET
receptor blockade with TAK044 (Fig. 1C and F), endothe-
lin-converting enzyme inhibition with phosphoramidon
(Fig. 1D and F) or NHE-1 blockade with HOE642 (Fig.
1E and F), giving support to the hypothesis that Ang II
promotes, at least at this dose and through AT1 receptors, the
release/formation of ET, which acting in an autocrine or
paracrine fashion activates the NHE-1 and determines the
contractile changes. A dose of exogenous ET-1 (5.0 nmol/l)
almost equipotent to 1.0 nmol/l Ang II (see Fig. 2A, typical
experiment) seems to utilize a pathway similar to that of the
octapeptide, since its PIE (21F 2%, n = 4, P < 0.05, Fig. 2A
and E) was cancelled by TAK044 (Fig. 2C and E) and by
HOE642 (Fig. 2D and E). The PIE of ET-1 was not
prevented by AT1 receptors blockade with losartan (force
increased by 18F 4%, n = 4, P < 0.05, Fig. 2B and E),
which allows the conclusion that Ang II acts through ET
but not ET through Ang II.
The enhanced NHE-1 activity caused by ET, either
when released in response to Ang II or when exogenously
applied, could potentially increase contractility by a myo-
filament-sensitising effect due to a rise in pHi and/or to an
increase in [Ca2 +]i secondary to a rise in [Na
+]i. Consistent
with our previous results [22–24], no significant changee traces of whole-cell currents before (Control) and after successive addition
mol/l HOE 642 (A). (B) Ni2 +-sensitive currents, obtained from currents of
ded in eight myocytes (C). Bars compare the ratio between control INCX and
inhibition prevented the ENCX negative shift, in agreement with the fact that
in Fig. 3. * Indicates P< 0.05 vs. control.
ascres/article-abstract/60/3/589/335517 by guest on 23 August 2019
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/cardiovascres/article-abstrain pHi was detected after addition of Ang II or ET-1 (Fig.
3A and C, respectively), thus rejecting pHi as a possible
cause of the PIE. The lack of changes in pHi after NHE-1
activation by Ang II or ET-1 is not a novel finding. We
have previously shown that in the presence of bicarbonate,
both peptides simultaneously activate the alkalinising
NHE-1 and the acidifying Na+-independent Cl/HCO3

exchanger, thus compensating changes in pHi [22,23].
Instead, the activation of the NHE-1 was evidenced by
an increase in [Na+]i that after 30 min was 2.2F 0.2 mmol/
l over control (n = 4, P < 0.05) for Ang II and 2.4F 0.4
mmol/l (n = 4, P < 0.05) for ET-1 (Fig. 3B and D, respec-
tively). In addition, the rise in [Na+]i caused by Ang II was
accompanied by an increase in peak systolic intracellular
Ca2 + from 0.674F 0.11 to 0.768F 0.13 Amol/l after Ang II
(n = 4, P < 0.05), without significant changes in diastolic
Ca2 + (0.310F 0.03 vs. 0.317F 0.03 Amol/l). Note that
the cancellation of the PIE by NHE-1 inhibition or ET
receptor blockade (Figs. 1 and 2) concurred with the
prevention of Ang II and ET-1-induced increase in [Na+]i
(Fig. 3B and D).
So far, the results clearly link the ET-mediated NHE-1
activation with the rise in [Na+]i and this rise with the PIE.
A plausible explanation for this link (indirectly supported
by previous experiments [13,14]) would be that the rise in
[Na+]i may produce a negative shift in the reversal potential
of the NCX (ENCX), thus allowing the NCX to operate in
reverse mode for more time during the action potential and
promoting cell Ca2 + influx. To analyse this hypothesis, the
effect of ET-1 on ENCX were examined in isolated myo-
cytes. Fig. 4A depicts representative traces of whole-cellFig. 6. Effects of reverse mode NCX inhibition on the inotropic response to An
comparisons. In the presence of KB-R7943, inhibitor of the reverse mode NCX,
averaged results after 30 min of Ang II]. Note that although KB-R7943 prevented
[Na+]i (D), giving support to the idea that the exchange between Nai
+ and Cae
2 + icurrents evoked by voltage-clamped descending ramps
before and after ET-1. Current density was dose-dependent-
ly increased by the peptide. The recorded currents were
mostly but not totally INCX since a remnant current was
present after NCX blockade with Ni2 +. This remnant Ni+ 2-
insensitive current was not affected by ET-1 (at 60 mV:
0.52F 0.18, 0.52F0.17 and 0.62F 0.19 pA/pF, in control,
1.0 and 10.0 nmol/l ET-1, respectively, n = 6) as it was also
reported by Zhang et al. [20] Fig. 4B shows the effect of
ET-1 on the Ni2 +-sensitive currents (representing INCX)
obtained by subtracting the currents recorded in Ni2 + to
those recorded in control and in the presence of ET-1.
Averaged values of ENCX before and after myocyte expo-
sure to 1.0 and 10.0 nmol/l ET-1 are shown in Fig. 4C. ET-1
produced a clear negative shift of ENCX (DENCX: 1.0 nmol/
l ET-1 = 10F 3 mV, 10.0 nmol/l ET-1 = 17.1F 5.1.
mV, n = 12, P < 0.05) and also induced an increase in both
outward and inward INCX, as can be appreciated by the INCX
recorded at 0 and  80 mV, respectively (Fig. 4D). In
agreement with previous reports [20,25], this increase
in INCX demonstrates a direct stimulation of the NCX by
ET-1.
The ET-1-induced negative shift in ENCX is likely to be
the result of the NHE-1 mediated increase in [Na+]i induced
by the peptide, since it was cancelled by preincubation with
HOE642. Representative current traces are shown in Fig.
5A and B. HOE642 did not affect basal ENCX value but
totally cancelled the negative shift (Fig. 5C; DENCX: 1.0
nmol/l ET-1 = 2.1F 3 mV, 10.0 nmol/l ET-1 = 1.7F 3.5
mV, n = 8). HOE642 did not prevent the ET-1-induced
increase in outward and inward INCX (Fig. 5D), confirmingg II. The typical force record of Fig. 1 is reproduced here (A) to facilitate
the contractile effect of Ang II was canceled [(C) typical force record; (B)
the increase in DF, it did not prevent or even slightly increased the rise in
s blocked. * Indicates P< 0.05 vs. pre-Ang II value.
ct/60/3/589/335517 by guest on 23 August 2019
Fig. 8. Inhibition of reverse mode NCX has no effect on basal contractility
nor on the increase in contractility promoted by extracellular Ca2 + increase.
Typical force records showing the lack of effect of 5 Amol/l KB-R7943 on
basal contractility (A, [Ca2 +]e = 1.35 mmol/l) and on the increase in
contractility of f 20% promoted by increasing [Ca2 +]e from 1.35 to 1.9
mmol/l (C). Overall results of DF (in g/mm2) for each type of experiments
[(B) n = 6 and (D) n = 4]. These results strongly suggest that KB-R7943 at
this concentration does not exert nonspecific actions that may affect
contractility.
N.G. Pe´rez et al. / Cardiovascular Research 60 (2003) 589–597 595
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/cardiovascres/article-abstract/6that it should be due to a direct effect of the peptide on the
NCX (probably by PKC-dependent protein phosphorylation
[25]).
Although we cannot rule out the possibility that in these
experiments, the activation of the NHE-1 could increase pHi
and induce HOE642-sensitive changes in membrane cur-
rents, the negative shift in the ENCX described here is
characteristic of a change in [Na+]i, which, on the other
hand, will favour the reverse working mode of the NCX. It
is important to note that the negative ENCX shift took place
despite the cells being dialyzed with a pipette solution of
constant [Na+], which very likely clamps bulk [Na+]i.
However, Na+ accumulation might occur at a certain mi-
cro-domain influencing ENCX to explain the present results.
In this regard, co-localization of NHE-1 and NCX was
previously reported [26,27].
The idea that a negative ENCX shift driving the reverse
mode NCX would contribute to the PIE induced by a low
dose of Ang II (or its proposed endogenous mediator ET) is
further supported by the experiments shown in Figs. 6 and
7. Blockade of the reverse mode NCX with KB-R7943 fully
prevented the increase in contractility induced by 1 nmol/
l Ang II (Fig. 6A–C). At the same time, it did not affect or
even slightly increased the rise in [Na+]i (Fig. 6D), giving
support to the idea that the Na+i for Ca
2 +
e exchange was
blocked. Interestingly, addition of KB-R7943 at the steady
state of the PIE due to 5 nmol/l ET-1 reverted the effect (Fig.
7A and B), while [Na+]i continued rising (Fig. 7C). Finally,
although it can be argued that KB-R7943 is not a specific
blocker of the reverse mode of the NCX, Fig. 8 shows that
the concentration used here did not affect basal contractility
(panels A and B) or the f 20% increase in contractilityFig. 7. Effects of reverse mode NCX inhibition on the inotropic response to
ET-1. Addition of KB-R7943 after full development of the PIE due to
exogenous ET-1 reverted the effect [(A) typical force record; (B) averaged
results after 30 min of ET-1] but did not prevent the increase in [Na+]i that
continued rising (C). * Indicates P < 0.05 vs. pre-ET-1 value. For the sake of
clarity, asterisks were only placed at 30 min of ET-1 and at 30 min of ET-
1 +KB-R7943.promoted by elevating [Ca2 +]e from 1.35 to 1.9 mmol/
l (panels C and D).0/3/589/335517 by guest on 23 August 20194. Discussion
Several of the effects classically thought to be due to Ang
II have been demonstrated to be mediated by the release/
formation of ET [1–12]. We are presenting here evidence
that the PIE of a low dose of Ang II is mediated by
activation of the AT1 subtype of receptors and a subsequent
release/formation of endogenous ET. Our results, although
based only in pharmacological interventions, indicate that
Ang II releases endogenous ET that, acting in an autocrine/
paracrine fashion, activates the NHE-1, which increases
[Na]i
+, activates the reverse mode NCX and promotes
Ca2 + influx to the cell. We should emphasize that our
experiments were performed after a1 and h1 receptors
blockade, thus eliminating the contribution of the known
Ang II-mediated catecholamine release effect [16].
In the absence of pHi changes, as in our experiments, the
PIE of ET (the proposed mediator of Ang II) should very
likely due to an increase in the Ca2 + transient. Yang et al.
[28] showed that the increase in the Ca2 + transient induced
by ET-1 is susceptible to inhibition of reverse mode NCX by
KB-R7943, and suggested, based on previous work, the
possibility of a synergistic contribution of L-type Ca2 +
channels [29,30] and the NCX [28] to the increase in the
Ca2 + transient. Our results are in agreement with this
possibility, but we propose that these two effects might be
dose dependent and would be dissected along the dose–
response curve: while the effect on NCX would be predom-
N.G. Pe´rez et al. / Cardiovascular Research 60 (2003) 589–597596
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/cardiovascres/article-absinant at the beginning of the curve, it will be undetectable at
maximal concentrations of ET. We consider that our pro-
posal gives an explanation for a recent report about a lack of
NCX contribution to the PIE of maximal doses of Ang II
[31], since, under this condition, the increase in Ca2 +
transient through the L-type Ca2 + channels would be the
predominant effect masking the contribution of NCX activ-
ity to the increase in Ca2 + transient. Furthermore, at
maximal pCa values, where saturation of Ca2 + binding sites
occurs, a change in the Ca2 + transient will not affect the
‘‘plateau’’ of the dose–response curve.
Based on previous results from our laboratory [21], we
could hypothesize that the Ang II-ET cross-talk is autocrine,
but the present data do not allow us to rule out the
participation of cells other than myocytes in this mecha-
nism. About the signaling pathway by which Ang II induces
the release/formation of ET, we should consider that current
evidence suggests that no granules of preformed ET are
stored in the cytoplasm [32]; therefore, it should be assumed
that ET release depends on de novo peptide formation. In
this regard, two mechanisms, not mutually exclusive, might
be involved: induction of gene expression [1–5,10] and/or
activation of endothelin-converting enzyme [6].
Finally, the question of which ET isoform and ET
receptor subtype are involved in the Ang II-ET cross-talk
cannot be answered from the present results. Furthermore,
the fact that in myocardium, both the ET-1 and ET-3
isoforms and the ETA and ETB subtype of receptors are
expressed, makes too speculative any assumption about this
matter.tract/60/3/589/335517 by guesAcknowledgements
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